Stoke Therapeutics, Inc. (STOK)
30.05
+0.24
(+0.81%)
USD |
NASDAQ |
Sep 08, 16:00
29.95
-0.10
(-0.33%)
Pre-Market: 08:34
Stoke Therapeutics EPS Diluted (Quarterly) : -0.9334 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.9334 |
| March 31, 2026 | -0.7929 |
| December 31, 2025 | -0.9922 |
| September 30, 2025 | -0.6543 |
| June 30, 2025 | -0.4024 |
| March 31, 2025 | 1.900 |
| December 31, 2024 | -0.1838 |
| September 30, 2024 | -0.4691 |
| June 30, 2024 | -0.4608 |
| March 31, 2024 | -0.5703 |
| December 31, 2023 | -0.5996 |
| September 30, 2023 | -0.5544 |
| June 30, 2023 | -0.6937 |
| March 31, 2023 | -0.53 |
| December 31, 2022 | -0.6506 |
| September 30, 2022 | -0.6624 |
| June 30, 2022 | -0.6279 |
| Date | Value |
|---|---|
| March 31, 2022 | -0.6582 |
| December 31, 2021 | -0.6637 |
| September 30, 2021 | -0.6147 |
| June 30, 2021 | -0.5984 |
| March 31, 2021 | -0.4583 |
| December 31, 2020 | -0.42 |
| September 30, 2020 | -0.4113 |
| June 30, 2020 | -0.392 |
| March 31, 2020 | -0.3356 |
| December 31, 2019 | -0.31 |
| September 30, 2019 | -0.2631 |
| June 30, 2019 | -1.538 |
| March 31, 2019 | -0.1759 |
| December 31, 2018 | -0.131 |
| September 30, 2018 | -0.1015 |
| June 30, 2018 | -0.0921 |
| March 31, 2018 | -0.0586 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Biogen, Inc. | 0.6557 |
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -61.62M |
| Revenue (Quarterly) | 9.325M |
| Total Expenses (Quarterly) | 70.94M |
| Enterprise Value | 1.585B |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | -660.8% |
| Earnings Yield | -11.22% |
| Normalized Earnings Yield | -11.22 |